Statistical performance comparison of different simultaneous global development designs for targeted drugs

Abstract

Abstract:

AIM: To evaluate the statistical performance of all-randomized design and enrichment design in simultaneous global development program for targeted drugs, and to provide a framework for the clinical practice. METHODS: Monte Carlo techniques were applied to simulate clinical data of simultaneous global development design for targeted drugs, and the power of all-randomized design and enrichment design was compared with different parameter settings.RESULTS:When the efficacy of non-targeted ethnic (NTE) patients and targeted ethnic (TE) patients, target positive and negative patients were equal, the power of all-randomized design and enrichment design with allocation was the highest, and the power of the enrichment design with screening was lower. When the target negative population had lower efficacy than the positive population, the enrichment design with allocation had the highest power, the second was all-randomized design, and the enrichment design with screening was the lowest. The power rose with the ratio of target positive population increased. When the efficacy of TE patients was lower than that of NTE patients, the results of power were almost the same with those in above, and the power was slightly lower. CONCLUSION: When there is sufficient evidence of a better effect on targeted positive patients than negative patients, the enrichment design is recommended. When researchers can't make sure that target drug is effective for marker-negative patients or not or there is not a reliable target diagnosis method, all-randomized design is recommended. And weighted Z test can provide enough power to verify the hypothesis when the sample size of local clinical trials is small.

Key words: targeted drugs, simultaneous global development program, power, enrichment design, all-randomized design

CLC Number:

R311

WANG Yafei, CHEN Feng, BAI Jianling, HUANG Lihong, YU Hao. Statistical performance comparison of different simultaneous global development designs for targeted drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1127-1132.

References

［1］ICH International Conference on Harmonization Guideline E5. Ethnic Factors in the Acceptability of Foreign Clinical Data［Z］.Step 4, February 1998.
［2］ Hsiao CF, Xu JZ, Liu JP.A group sequential approach to evaluation of bridging studies［J］. J Biopharm Stat, 2003,13(4): 793-801.
［3］Chow SC, Chiang C, Liu JP, et al. Statistical methods for bridging studies［J］. J Biopharm Stat, 2012,22(5): 903-915.
［4］Gould AL, Jin T, Zhang LX, et al.A predictive Bayesian approach to the design and analysis of bridging studies［J］. J Biopharm Stat, 2012, 22(5): 916-934.
［5］Ministry of Health, Labor and Welfare of Japan, Basic Principles on Global Clinical Trials［Z］. September 28, 2007.
［6］Huang Q, Chen G, Yuan Z, et al.Design and sample size considerations for simultaneous global drug development program［J］. J Biopharm Stat, 2012,22(5): 1060-1073.
［7］Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours［J］. Nature, 2000, 406(6797): 747-752.
［8］Shipp MA, Ross KN, Tamayo P, et al.Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning［J］. Nat Med, 2002,8(1): 68-74.
［9］Sargent D, Allegra C.Allegra, Issues in clinical trial design for tumor marker studies［J］. Semin Oncol, 2002, 29(3): 222-230.
［10］Freidlin B, McShane LM, Korn EL.Randomized clinical trials with biomarkers: design issues［J］. J Natl Cancer Inst, 2010,102(3): 152-160.
［11］Liu K, Yuan Z, Chen G, et al.Statistical properties of the design for simultaneous global drug development program［J］. J Biopharm Stat, 2015,25(6): 1135-1144.
［12］陈林.靶向临床试验设计性能评价及效应大小估计研究［D］. 南方医科大学，2013.
［13］FDA Food and Drug Administration.Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics［Z］. May, 2007.
［14］Jácome AA,Wohnrath DR, Scapulatempo Neto C,et al. Prognostic value of epidermal growth factor receptors in gastric cancer：a survival analysis by Weibull model incorporating long-term survivors［J］.Gastric Cancer,2014,17(1): 76-86.
［15］Yang B, Zhou Y, Zhang L, et al. Enrichment design with patient population augmentation［J］. Contemp Clin Trials, 2015,42: 60-67.

[1]	DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning. Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181.
[2]	SHANG Feng, YU Chengkai, YANG Peng. Bridging method of adjusted significance levels α' in the target region concerning superiority design for normal data distribution in MRCT [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 59-64.
[3]	LU Mengjie, LIU Yuxiu, LU Guangming, ZHANG Longjiang, HUANG Wei, GE Aichen. Sample size calculation for single-arm OPC trials with multi endpoints [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 917-921.
[4]	CHU Jiru, SHEN Jie. Mechanism of the inhibition of apoptosis by survivin during high fluence low-power laser irradiation-induced apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 640-644.
[5]	CHEN Lin, LIU Yu-xiu, MIAO Hua-zhang. Statistical performance comparison of different design methods of targeted clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 399-403.
[6]	WEN Shi-mei, CHEN Yun-fei, LIU Hua. SAS programming for sample size and power calculation of measurement data in non-inferior trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 51-54.
[7]	LI Chan-juan, JIANG Zhi-wei, WANG Rui, XIA Jie-lai. Sample size estimation in randomized controlled drug clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1132-1136.
[8]	LU Jing-Jing, YU Hao¹, CHEN Feng¹. Comparison of testing approaches to establishing equivalence on proportions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(3): 354-357.
[9]	ZHANG Gao-Kui, YAO Chen, XIA Jie-Lai. Simulation method on power and sample size calculation in related rate non-inferior trial [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(2): 234-237.
[10]	ZHENG Qing-Shan, SUN Rui-Yuan, CHEN Zhi-Yang. Determination of equivalence of two drugs in clinical trial [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 559-561.